We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.
- Authors
Morrow, Phuong Khanh; Murthy, Rashmi K; Ensor, Joe D; Gordon, Gilad S; Margolin, Kim A; Elias, Anthony D; Urba, Walter J; Weng, David E; Rugo, Hope S; Hortobagyi, Gabriel N
- Abstract
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast cancer (MBC). VEGF binds to 2 receptors on endothelial cells, VEGFR-1 and VEGFR-2. RPI.4610 (Angiozyme0) is an antiangiogenic ribozyme targeting the VEGFR-1 mRNA. Preclinical and phase 1 studies suggested that RPI.4610 is a well-tolerated agent with clinical activity in solid tumors. The authors' trial evaluated the efficacy of RPI.4610 in the treatment of patients with progressive MBC.
- Publication
Cancer, 2012, Vol 118, Issue 17, p4098
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.26730